{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:35:45Z","timestamp":1776836145099,"version":"3.51.2"},"reference-count":60,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: COVID-19 remains a substantial public health challenge in the Netherlands. Next-generation COVID-19 vaccine, mRNA-1283, is approved in the European Union, with potential for higher relative vaccine efficacy compared with originally licensed COVID-19 vaccines. Methods: The potential public health and economic impact of mRNA-1283 in adults \u2265 60 years and high-risk adults aged 18\u201359 years was modeled versus no vaccination and originally licensed mRNA-1273 and BNT162b2, adapting a published static Markov model with a 1-year time horizon. COVID-19 burden reflected two full post-pandemic seasons. Vaccine efficacy versus mRNA-1273 was based on pivotal phase 3 NextCOVE trial data; efficacy versus BNT162b2 was derived from an indirect treatment comparison. The economically justifiable price (EJP) of mRNA-1283 versus no vaccination and price premiums over existing vaccines were determined at a willingness-to-pay threshold of \u20ac50,000\/quality-adjusted life-year (QALY) gained. Results: Without COVID-19 vaccination, an estimated 460,000 infections, 23,800 hospitalizations, and 5300 deaths would occur. With current coverage, mRNA-1283 was estimated to prevent 68,000 infections, 5400 hospitalizations, and 1200 deaths, saving 9667 QALYs and over \u20ac66.5 million in treatment costs. The EJP was \u20ac238 versus no vaccination. Compared with mRNA-1273 and BNT162b2, mRNA-1283 was estimated to prevent additional burden (e.g., 1309 and 1679 hospitalizations, respectively) and was cost-effective at an incremental EJP of \u20ac62 versus mRNA-1273 and \u20ac80 versus BNT162b2. Conclusions: The results support continued COVID-19 vaccination to mitigate the ongoing health and societal burden of SARS-CoV-2 in the Netherlands. The comparative analyses indicate that mRNA-1283 may be associated with substantial health benefits over originally licensed mRNA vaccines; consequently, its use may further improve health outcomes and economic efficiency within COVID-19 vaccination programs.<\/jats:p>","DOI":"10.3390\/vaccines14040364","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:01:22Z","timestamp":1776686482000},"page":"364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-1001","authenticated-orcid":false,"given":"Simon","family":"van der Pol","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands"},{"name":"Health-Ecore, 3704HE Zeist, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-9190","authenticated-orcid":false,"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[{"name":"Moderna, Inc., Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0510-3365","authenticated-orcid":false,"given":"Tjalke","family":"Westra","sequence":"additional","affiliation":[{"name":"Moderna Netherlands, 1082MC Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands"},{"name":"Health-Ecore, 3704HE Zeist, The Netherlands"},{"name":"Department of Economics, Econometrics and Finance, University of Groningen, 9747AE Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[{"name":"Health-Ecore, 3704HE Zeist, The Netherlands"},{"name":"Department of Management Sciences, Open University, 6401DL Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1473-3099(25)00236-1","article-title":"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): Results from a phase 3, randomised, observer-blind, active-controlled trial","volume":"25","author":"Chalkias","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025\u20132026","volume":"393","author":"Scott","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240222","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: A systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_6","first-page":"2300703","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023","volume":"29","author":"Valk","year":"2024","journal-title":"Eurosurveillance"},{"key":"ref_7","unstructured":"Gezondheidsraad (2026, January 29). COVID-19-Vaccinatie in 2025. Available online: https:\/\/www.gezondheidsraad.nl\/site\/binaries\/site-content\/collections\/documents\/2025\/03\/27\/advies-covid-19-vaccinatie-in-2025\/COVID-19-vaccinatie-in-2025-advies.pdf."},{"key":"ref_8","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2026, January 29). Staat van Infectieziekten in Nederland, 2024. RIVM Rapport 2025-0123. Available online: https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2025-0123.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s12325-025-03112-y","article-title":"Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands","volume":"42","author":"Zeevat","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_10","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2026, January 29). Deelname COVID-19-Vaccinatie in Nederland. Available online: https:\/\/www.rivm.nl\/sites\/default\/files\/2025-12\/Deelname-COVID-19-vaccinatie-in-Nederland_20251208.pdf."},{"key":"ref_11","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2026, February 02). Infectie Radar. Available online: https:\/\/www.infectieradar.nl\/."},{"key":"ref_12","unstructured":"European Medicines Agency (EMA) (2026, February 13). mNexspike. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mnexspike#overview."},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2026, February 02). Spikevax: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax#product-info."},{"key":"ref_14","unstructured":"Food & Drug Administration (FDA) (2026, February 02). MNEXSPIKE\u2014Package Insert, Available online: https:\/\/www.fda.gov\/media\/186738\/download?attachment."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kopel, H., Nguyen, V.H., Boileau, C., Bogdanov, A., Winer, I., Ducruet, T., Zeng, N., Bonafede, M., Esposito, D.B., and Martin, D. (2023). Comparative Effectiveness of Bivalent (Original\/Omicron BA.4\/BA.5) COVID-19 Vaccines in Adults. Vaccines, 11.","DOI":"10.3390\/vaccines11111711"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans","volume":"386","author":"Dickerman","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamainternmed.2022.2109","article-title":"Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans","volume":"182","author":"Dickerman","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40121-024-00936-z","article-title":"Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework","volume":"13","author":"Kavikondala","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s12325-025-03117-7","article-title":"Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE","volume":"42","author":"Wang","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/03007995.2025.2466726","article-title":"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults","volume":"41","author":"Beck","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/13696998.2026.2624967","article-title":"Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United States","volume":"29","author":"Fust","year":"2026","journal-title":"J. Med. Econ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1080\/13696998.2025.2549630","article-title":"The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada","volume":"28","author":"Fust","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_23","unstructured":"University of Michigan COVID-19 Vaccination Modeling Team (2026, April 07). Economic Analysis of an Additional Dose of the 2024\u20132025 COVID-19 Vaccine, Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/05-COVID-Prosser-508.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"126948","DOI":"10.1016\/j.vaccine.2025.126948","article-title":"Cost-effectiveness of routine COVID-19 adult vaccination programmes in England","volume":"53","author":"Keeling","year":"2025","journal-title":"Vaccine"},{"key":"ref_25","unstructured":"Centraal Bureau voor de Statistiek (CBS) (2026, February 02). Inflation, Available online: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-consumentenprijzen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jval.2025.03.002","article-title":"The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level","volume":"28","author":"Geuzinge","year":"2025","journal-title":"Value Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.vaccine.2023.04.069","article-title":"Cost-effectiveness of routine annual influenza vaccination by age and risk status","volume":"41","author":"Gebremariam","year":"2023","journal-title":"Vaccine"},{"key":"ref_28","first-page":"101472","article-title":"Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: A prospective cohort study with pre- and post-infection data","volume":"59","author":"Huiberts","year":"2025","journal-title":"Lancet Reg. Health\u2013Eur."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e042670","DOI":"10.1161\/JAHA.125.042670","article-title":"Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis","volume":"14","author":"Kawai","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(23)00684-9","article-title":"Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: A cohort study","volume":"24","author":"Xie","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40121-025-01292-2","article-title":"Evaluating the Effectiveness of 2024\u20132025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged \u2265 18 years in the United States: An Observational Matched Cohort Study","volume":"15","author":"Vicic","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1473-3099(22)00409-1","article-title":"Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant","volume":"22","author":"Higdon","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e001074","DOI":"10.1136\/bmjmed-2024-001074","article-title":"Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: Target trial emulation based on registry data","volume":"3","author":"Andersson","year":"2024","journal-title":"BMJ Med."},{"key":"ref_34","unstructured":"US Food & Drug Administration (FDA) (2026, January 29). Letters for Myocarditis, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pijpers, J., van Roon, A., van Roekel, C., Labuschagne, L., Smagge, B., Ferreira, J.A., de Melker, H., and Hahn\u00e9, S. (2023). Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study. Vaccines, 11.","DOI":"10.1101\/2023.08.03.23293593"},{"key":"ref_36","unstructured":"Centraal Bureau voor de Statistiek (CBS) (2026, February 02). Bevolking, Available online: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-bevolking."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/infdis\/jiab118","article-title":"Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom","volume":"226","author":"Zeevat","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1016\/j.vaccine.2009.05.042","article-title":"Internet-based monitoring of influenza-like illness in the general population: Experience of five influenza seasons in the Netherlands","volume":"27","author":"Friesema","year":"2009","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejor.2021.12.044","article-title":"Modeling COVID-19 hospital admissions and occupancy in the Netherlands","volume":"304","author":"Bekker","year":"2023","journal-title":"Eur. J. Oper. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1016\/j.vaccine.2024.04.040","article-title":"Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations","volume":"42","author":"Zeevat","year":"2024","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127735","DOI":"10.1016\/j.vaccine.2025.127735","article-title":"Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands","volume":"65","author":"Zeevat","year":"2025","journal-title":"Vaccine"},{"key":"ref_42","unstructured":"StatLine Opendata.CBS.NL (2026, January 29). Ziekenhuisopnamen en-Pati\u00ebnten; Diagnose-Indeling ICD-10 (3-Teken Niveau). Available online: https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/84069NED\/table?ts=1767789775076."},{"key":"ref_43","unstructured":"Gezondheidsraad (2026, February 05). RSV-Vaccinatie Voor Ouderen. Available online: https:\/\/www.gezondheidsraad.nl\/site\/binaries\/site-content\/collections\/documents\/2025\/03\/27\/advies-rsv-vaccinatie-voor-ouderen\/RSV-vaccinatie-voor-ouderen_advies.pdf."},{"key":"ref_44","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2026, February 05). Staat van Infectieziekten in Nederland, 2023. RIVM-Rapport 2024-0135. Available online: https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2024-0135.pdf."},{"key":"ref_45","first-page":"D5423","article-title":"Sterfte en heropname na ziekenhuisopname met covid-19","volume":"164","author":"Leijte","year":"2020","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajem.2021.10.059","article-title":"Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis","volume":"51","author":"Ramzi","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"ref_47","unstructured":"Klein, N. (2026, February 02). Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-Time Within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis. Presentation to the Advisory Committee on Immunization Practices, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/109493."},{"key":"ref_48","unstructured":"SNPG.nl (2026, April 10). Vergoeding. Available online: https:\/\/www.snpg.nl\/article\/griep-ha-afronden\/declareren-griepvaccinaties\/vergoeding\/."},{"key":"ref_49","unstructured":"Nederland, Z. (2023, June 20). Richtlijn voor Het Uitvoeren van Economische Evaluaties in de Gezondheidszorg. Available online: https:\/\/www.zorginstituutnederland.nl\/documenten\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","article-title":"Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis","volume":"33","author":"Rozenbaum","year":"2015","journal-title":"Vaccine"},{"key":"ref_51","unstructured":"Dagblad van het Noorden (2026, April 10). Veel Mensen Die Ziek Zijn Door Post-COVID Gaan Gewoon Naar Hun Werk. Vooral Vrouwen en Hoogopgeleiden. Zo Zit Dat. Available online: https:\/\/dvhn.nl\/meer\/gezond\/Een-op-vijf-pati%C3%ABnten-werkt-door-met-post-covid-blijkt-uit-Gronings-onderzoek.-Gezond-is-dat-niet.-Vooral-vrouwen-en-hogeropgeleiden-werken-met-klachten.-Hoe-kan-dat-43254815.html."},{"key":"ref_52","unstructured":"Medicijnkosten.nl (2026, April 10). Tramadol HCL\/Paracetam Aur Tab Filmomh 37.5\/325 mg. Available online: https:\/\/www.medicijnkosten.nl\/medicijn?artikel=TRAMADOL+HCL%2FPARACETAM+AUR+TAB+FILMOMH+37%2C5%2F325MG&id=07d21c743d7c5877b89d9ef18330e005."},{"key":"ref_53","unstructured":"StatLine Opendata CBS NL (2026, April 10). Werkzame Beroepsbevolking; Arbeidsduur, 2003\u20132022. Available online: https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/82647NED\/table."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1016\/j.vaccine.2005.06.007","article-title":"Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults","volume":"23","author":"Postma","year":"2005","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"576","DOI":"10.7326\/M20-5661","article-title":"Sixty-Day Outcomes Among Patients Hospitalized With COVID-19","volume":"174","author":"Chopra","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_56","unstructured":"van Zon, S. (2026, April 10). Presentation at ACTION Conference April 13, 2023. Werkfunctioneren en Ziekteverzuim Bij Post-COVID-Syndroom. Available online: https:\/\/www.actioncovid.nl\/werkfunctioneren."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2443166","DOI":"10.1001\/jamanetworkopen.2024.43166","article-title":"Safety of Simultaneous vs. Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial","volume":"7","author":"Walter","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_58","unstructured":"University of Michigan COVID-19 Vaccination Modeling Team (2026, February 02). Economic Analysis of COVID-19 Vaccination, Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/05-COVID-Prosser-508.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1093\/cid\/ciac151","article-title":"Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases with Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison with Controls","volume":"75","author":"Sandmann","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","unstructured":"PHOSP-COVID Collaborative Group (2022). Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir. Med., 10, 761\u2013775."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:36:06Z","timestamp":1776832566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["vaccines14040364"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14040364","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}